Halozyme Therapeutics (HALO)
(Delayed Data from NSDQ)
$38.46 USD
-0.66 (-1.69%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $38.49 +0.03 (0.08%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum A VGM
Brokerage Reports
0 items in cart
Halozyme Therapeutics, Inc. [HALO]
Reports for Purchase
Showing records 1 - 20 ( 181 total )
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2023 Financial Results; Revenue Essentially In Line; Raising PT to $50
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Three Enhanze-Related Approvals Achieved This Week; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Long-Term Financial Guidance; Patent Protections Detailed; Lowering PT to $48
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We Remain Confident in DARZALEX FASPRO; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for HALO 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department